Antitrust Trouble For Turing? NY Opens Probe
This article was originally published in Scrip
The negative publicity Turing Pharmaceuticals AG has been garnering over the past month for its nearly 5,500% increase of its toxoplasmosis medicine Daraprim (pyrimethamine), which quickly became a presidential election issue, has now grabbed the attention of antitrust investigators in New York.
Register for our free email digests: